Drug Profile
FP 02.2
Alternative Names: FP 02; FP-02-2; FP02.2; Hepatitis-V-vaccine-Vaxin; Hepsyn-B™; HepTcellLatest Information Update: 20 Apr 2023
Price :
$50
*
At a glance
- Originator Immune Targeting Systems
- Developer Altimmune
- Class Hepatitis B vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 20 Apr 2023 Altimmune has patents pending for HBV immunotherapy technology directed to compositions comprising fluorocarbon constructs with specific peptide HBV antigen sequences technology)
- 11 Apr 2023 Altimmune completes enrolment in the phase II HepTcell immunotherapy in patients with inactive chronic hepatitis B (CHB) trial for Hepatitis B in North America, Europe and Southeast Asia(IM, Injection) (NCT04684914)
- 30 Dec 2020 Phase-II clinical trials in Hepatitis B in Canada, USA (IM)